METRODORA Trademark

Trademark Overview


On Sunday, September 12, 2021, a trademark application was filed for METRODORA with the United States Patent and Trademark Office. The USPTO has given the METRODORA trademark a serial number of 97023419. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, May 23, 2024. This trademark is owned by Metrodora Institute LLC. The METRODORA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; pharmaceutical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic str...
metrodora

General Information


Serial Number97023419
Word MarkMETRODORA
Filing DateSunday, September 12, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, May 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 28, 2023

Trademark Statements


Goods and ServicesPharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; pharmaceutical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; therapeutic pharmaceuticals for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; medical preparations for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries; prescription diets, namely, dietetic foods and nutritional and dietary supplements provided by prescription for the treatment of complex or rare multisystem disorders, namely, autoimmune disorders, autonomic nervous system disorders, microbiota-gut-brain axis disorders, concussions, connective tissue disorders, dysautonomia, gastrointestinal disorders, gastrointestinal motility disorders, genetic disorders, headaches, immunological disorders, neurocognitive disorders, neurological disorders, neurogastrointestinal disorders, pain, post-traumatic stress disorder, rheumatic disorders, or traumatic brain injuries
Pseudo MarkMETRO DORA

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 20, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMetrodora Institute LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressSalt Lake City, UT 84103

Party NameMetrodora Institute LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSalt Lake City, UT 84103

Trademark Events


Event DateEvent Description
Wednesday, September 15, 2021NEW APPLICATION ENTERED
Wednesday, October 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 15, 2022ASSIGNED TO EXAMINER
Thursday, June 23, 2022NON-FINAL ACTION WRITTEN
Thursday, June 23, 2022NON-FINAL ACTION E-MAILED
Thursday, June 23, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 22, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 23, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 3, 2023EXAMINERS AMENDMENT -WRITTEN
Friday, February 3, 2023EXAMINERS AMENDMENT E-MAILED
Friday, February 3, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, February 3, 2023ASSIGNED TO LIE
Friday, February 3, 2023EXAMINER'S AMENDMENT ENTERED
Friday, February 17, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 8, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 28, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 28, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 23, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 14, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 14, 2023SOU EXTENSION 1 FILED
Tuesday, November 14, 2023SOU EXTENSION 1 GRANTED
Thursday, November 16, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 23, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 23, 2024SOU EXTENSION 2 FILED
Thursday, May 23, 2024SOU EXTENSION 2 GRANTED
Friday, May 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED